Condition: Sickle Cell Disease · Sponsor: Children's National Research Institute
This multicenter prospective study seeks to determine if daratumumab given, prior to HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus, can prevent pure red blood cell aplasia with an acceptable safety profile in patients with anti-donor red blood cell antibodies, achieving an event-free survival similar to transplanted patients without such antibodies.
This description comes directly from the study's public registry record.
Robert Nickel, MD · 202-476-3122 · rnickel@childrensnational.org
Maryanne Odinakachukwu · 202-476-2957 · modinakach@childrensnational.org
Always discuss trial participation with your own doctor first.
| Children's National Hospital | Washington D.C., District of Columbia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06358638